{"id":"3abcee20-9bbb-449b-87de-4be653713edf","url":"https://clinicalintelpulse.theaslangroupllc.com/api/clinical/pipeline-scan?condition=Disease+or+condition+%E2%80%94+e.g.+%22Non-Small+Cell+Lung+Cancer%22+%7C+%22Alzheimer+Disease%22+%7C+%22Type+2+Diabetes%22+%7C+%22Crohn+Disease%22+%7C+%22Multiple+Myeloma%22&lang=en+%7C+es+%7C+fr+%7C+de+%7C+ja+%7C+zh+%7C+ko+%7C+pt+%7C+ar+%7C+hi+%28default%3A+en%29&phase=phase2+%7C+phase3+%7C+both+%28default%3A+both%29&status=active+%7C+all+%28default%3A+active+%E2%80%94+recruiting+%2B+active+not+recruiting%29","method":"GET","fingerprint":"229e7db2c2f25479cdbb62ff2c6eabe68fe18b8a053a0e78ee7d763f55cf1402","name":"ClinicalIntelPulse","description":null,"category":"other","docs_url":null,"advertised_price_usd":"0.150000","asset":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","scheme":"exact","networks":["eip155:8453","solana:5eykt4UsFv8P8NJdTREpY1vzqKqZKvdp","eip155:137","eip155:42161","eip155:480","eip155:143","eip155:196","eip155:999","algorand:wGHE2Pwdvd7S12BL5FaOP20EGYesN73k","xrpl:0","eip155:56"],"pay_to":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","input_schema":{"type":"object","required":["type","method"],"properties":{"type":{"type":"string","const":"http"},"method":{"enum":["GET","HEAD","DELETE"],"type":"string"},"queryParams":{"type":"object","properties":{"lang":{"type":"string"},"phase":{"type":"string"},"status":{"type":"string"},"condition":{"type":"string"}}}},"additionalProperties":false},"output_schema":{"type":"object","required":["type"],"properties":{"type":{"type":"string"},"errors":{"type":"object","description":"Documented error responses, keyed by HTTP status code","additionalProperties":{"type":"object","required":["description"],"properties":{"example":{"type":"object"},"description":{"type":"string"}}}},"example":{"type":"object"}}},"schema_completeness":0,"status":"live","first_seen_at":"2026-08-23 12:49:14.405885+00","last_seen_at":"2026-08-23 16:55:04.262+00","last_success_at":"2026-09-14 16:30:14.384+00","dead_since":null,"probe_backoff_tier":0,"next_probe_at":"2026-09-14 16:35:14.384+00","search_tsv":"'clinicalintelpuls':1","catalog_number":"5209","x402_version":2,"resource_url":"https://clinicalintelpulse.theaslangroupllc.com/api/clinical/pipeline-scan","resource_description":"Clinical trial pipeline scan for any disease — all active Phase 2/3 trials with trial counts, sponsor landscape, geographic distribution, mechanism breakdown and pipeline density, across 400,000+ trials worldwide. For biotech-investing and pharma agents.","bazaar_extension":{"info":{"input":{"type":"http","method":"GET","queryParams":{"lang":"en | es | fr | de | ja | zh | ko | pt | ar | hi (default: en)","phase":"phase2 | phase3 | both (default: both)","status":"active | all (default: active — recruiting + active not recruiting)","condition":"Disease or condition — e.g. \"Non-Small Cell Lung Cancer\" | \"Alzheimer Disease\" | \"Type 2 Diabetes\" | \"Crohn Disease\" | \"Multiple Myeloma\""}},"output":{"type":"json","errors":{"400":{"example":{"error":"invalid request"},"description":"Invalid or missing parameter(s). Returned before the payment gate on paid requests, so a malformed call is never charged. JSON body: { error: <what is wrong and how to fix it> } plus usage hints."},"402":{"description":"Payment required — x402 v2 challenge; the accepts array lists scheme, network, and amount. Retry the same request with a PAYMENT-SIGNATURE (v2) or X-PAYMENT (v1) header. Verification is free."},"500":{"example":{"error":"upstream_failed"},"description":"Unexpected server error. If a payment settled without a usable result, contact info@theaslangroupllc.com with the settlement tx hash for a re-run or credit."}},"example":{"query_summary":{"condition":"Non-Small Cell Lung Cancer","status_filter":"RECRUITING,ACTIVE_NOT_RECRUITING","phases_searched":["PHASE2","PHASE3"]},"pipeline_totals":{"phase2_count":156,"phase3_count":89,"total_active":245},"phase3_highlights":[{"nctId":"NCT05116748","title":"Pembrolizumab + Carboplatin vs SOC in NSCLC","status":"RECRUITING","sponsor":"Merck","countries":["United States","Germany","Japan","South Korea"],"primaryCompletion":"2026-03"}],"sponsor_landscape":{"academic_sponsors":"ECOG-ACRIN, Alliance, NCI leading academic cooperative groups","emerging_biotechs":["Turning Point Therapeutics","Blueprint Medicines","Mirati Therapeutics"],"top_industry_sponsors":["Roche/Genentech (18 trials)","Bristol-Myers Squibb (14)","AstraZeneca (13)","Merck (12)","Pfizer (11)"]},"mechanism_breakdown":{"adc":18,"other":81,"bispecific":12,"targeted_therapy":41,"chemo_combinations":31,"io_checkpoint_inhibitors":62},"pipeline_assessment":"Extremely crowded pipeline — PD-1/L1 space saturated. ADCs and bispecifics represent highest differentiation potential. KRAS G12C targeted therapies emerging as new standard.","approved_drugs_context":"NSCLC has 30+ FDA-approved agents. Pipeline is additive rather than disruptive in most cases.","geographic_distribution":{"asia_pct":22,"other_pct":5,"europe_pct":28,"us_trials_pct":45,"most_active_countries":["United States","China","Germany","South Korea","Japan"]}}}},"schema":{"type":"object","$schema":"https://json-schema.org/draft/2020-12/schema","required":["input"],"properties":{"input":{"type":"object","required":["type","method"],"properties":{"type":{"type":"string","const":"http"},"method":{"enum":["GET","HEAD","DELETE"],"type":"string"},"queryParams":{"type":"object","properties":{"lang":{"type":"string"},"phase":{"type":"string"},"status":{"type":"string"},"condition":{"type":"string"}}}},"additionalProperties":false},"output":{"type":"object","required":["type"],"properties":{"type":{"type":"string"},"errors":{"type":"object","description":"Documented error responses, keyed by HTTP status code","additionalProperties":{"type":"object","required":["description"],"properties":{"example":{"type":"object"},"description":{"type":"string"}}}},"example":{"type":"object"}}}}}},"accepted_requirements":[{"raw":{"asset":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","extra":{"name":"USD Coin","version":"2"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"150000","scheme":"exact","network":"eip155:8453","maxTimeoutSeconds":300},"asset":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:8453","amountAtomic":"150000"},{"raw":{"asset":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","extra":{"name":"GatewayWalletBatched","version":"1","verifyingContract":"0x77777777dcc4d5a8b6e418fd04d8997ef11000ee"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"150000","scheme":"exact","network":"eip155:8453","maxTimeoutSeconds":604900},"asset":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:8453","amountAtomic":"150000"},{"raw":{"asset":"EPjFWdd5AufqSSqeM2qN1xzybapC8G4wEGGkZwyTDt1v","extra":{"feePayer":"BFK9TLC3edb13K6v4YyH3DwPb5DSUpkWvb7XnqCL9b4F"},"payTo":"985iFjbnGQ3dJcwXnfRCMSrH4Jnc3kW1N6msR64B5KX1","amount":"150000","scheme":"exact","network":"solana:5eykt4UsFv8P8NJdTREpY1vzqKqZKvdp","maxTimeoutSeconds":300},"asset":"EPjFWdd5AufqSSqeM2qN1xzybapC8G4wEGGkZwyTDt1v","payTo":"985iFjbnGQ3dJcwXnfRCMSrH4Jnc3kW1N6msR64B5KX1","scheme":"exact","network":"solana:5eykt4UsFv8P8NJdTREpY1vzqKqZKvdp","amountAtomic":"150000"},{"raw":{"asset":"0x3c499c542cEF5E3811e1192ce70d8cC03d5c3359","extra":{"name":"USD Coin","version":"2"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"150000","scheme":"exact","network":"eip155:137","maxTimeoutSeconds":300},"asset":"0x3c499c542cEF5E3811e1192ce70d8cC03d5c3359","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:137","amountAtomic":"150000"},{"raw":{"asset":"0xaf88d065e77c8cC2239327C5EDb3A432268e5831","extra":{"name":"USD Coin","version":"2"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"150000","scheme":"exact","network":"eip155:42161","maxTimeoutSeconds":300},"asset":"0xaf88d065e77c8cC2239327C5EDb3A432268e5831","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:42161","amountAtomic":"150000"},{"raw":{"asset":"0x79A02482A880bCe3F13E09da970dC34dB4cD24D1","extra":{"name":"USDC","version":"2"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"150000","scheme":"exact","network":"eip155:480","maxTimeoutSeconds":300},"asset":"0x79A02482A880bCe3F13E09da970dC34dB4cD24D1","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:480","amountAtomic":"150000"},{"raw":{"asset":"0x754704Bc059F8C67012fEd69BC8A327a5aafb603","extra":{"name":"USDC","version":"2"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"150000","scheme":"exact","network":"eip155:143","maxTimeoutSeconds":300},"asset":"0x754704Bc059F8C67012fEd69BC8A327a5aafb603","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:143","amountAtomic":"150000"},{"raw":{"asset":"0x779ded0c9e1022225f8e0630b35a9b54be713736","extra":{"name":"USD₮0","version":"1"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"150000","scheme":"exact","network":"eip155:196","maxTimeoutSeconds":300},"asset":"0x779ded0c9e1022225f8e0630b35a9b54be713736","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:196","amountAtomic":"150000"},{"raw":{"asset":"0xb88339CB7199b77E23DB6E890353E22632Ba630f","extra":{"name":"USDC","version":"2"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"150000","scheme":"exact","network":"eip155:999","maxTimeoutSeconds":300},"asset":"0xb88339CB7199b77E23DB6E890353E22632Ba630f","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:999","amountAtomic":"150000"},{"raw":{"asset":"31566704","extra":{"feePayer":"ZMFK2OI7ZBD2U27ISERZC4S6LKM6WMFJPZQ4MYNJDZ2VNBNMBA67RA22AA"},"payTo":"62A253YPATFNJCPRKID3FKD77MYJFNTVRYRP4B4JWG36EGLPY7UXFWGI7I","amount":"150000","scheme":"exact","network":"algorand:wGHE2Pwdvd7S12BL5FaOP20EGYesN73k","maxTimeoutSeconds":300},"asset":"31566704","payTo":"62A253YPATFNJCPRKID3FKD77MYJFNTVRYRP4B4JWG36EGLPY7UXFWGI7I","scheme":"exact","network":"algorand:wGHE2Pwdvd7S12BL5FaOP20EGYesN73k","amountAtomic":"150000"},{"raw":{"asset":"XRP","extra":{"invoiceId":"0EF5EE18B3CF44559F1503F6E0BA510B","sourceTag":804681468},"payTo":"rMnHeutYALco8RYFVcmuU4BCgSzBpPEh32","amount":"150000","scheme":"exact","network":"xrpl:0","maxTimeoutSeconds":300},"asset":"XRP","payTo":"rMnHeutYALco8RYFVcmuU4BCgSzBpPEh32","scheme":"exact","network":"xrpl:0","amountAtomic":"150000"},{"raw":{"asset":"524C555344000000000000000000000000000000","extra":{"issuer":"rMxCKbEDwqr76QuheSUMdEGf4B9xJ8m5De","invoiceId":"B69C458AC46A4EFA88BB1A18A21C23C0","sourceTag":804681468},"payTo":"rMnHeutYALco8RYFVcmuU4BCgSzBpPEh32","amount":"0.15","scheme":"exact","network":"xrpl:0","maxTimeoutSeconds":300},"asset":"524C555344000000000000000000000000000000","payTo":"rMnHeutYALco8RYFVcmuU4BCgSzBpPEh32","scheme":"exact","network":"xrpl:0","amountAtomic":"0.15"},{"raw":{"asset":"0x8d0D000Ee44948FC98c9B98A4FA4921476f08B0d","extra":{"name":"World Liberty Financial USD","version":"1","signerAddress":"0x34F7a661160780Ce1346e6D7B96D2bE244590899","assetTransferMethod":"eip3009"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"150000000000000000","scheme":"exact","network":"eip155:56","maxTimeoutSeconds":300},"asset":"0x8d0D000Ee44948FC98c9B98A4FA4921476f08B0d","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:56","amountAtomic":"150000000000000000"}],"bazaar_compatible":true,"bazaar_validated_at":"2026-09-14 16:30:14.384+00","bazaar_validation_error":null,"window":"24h","probes_n":18,"handshake_uptime":1,"settle_success_rate":0,"valid_result_rate":null,"latency_p50":578,"latency_p90":6702,"price_drift_pct":0,"score":0.5403,"computed_at":"2026-09-14 16:30:25.242+00","source_metadata":[{"raw":{"url":"https://clinicalintelpulse.theaslangroupllc.com/api/clinical/pipeline-scan?condition=Disease+or+condition+%E2%80%94+e.g.+%22Non-Small+Cell+Lung+Cancer%22+%7C+%22Alzheimer+Disease%22+%7C+%22Type+2+Diabetes%22+%7C+%22Crohn+Disease%22+%7C+%22Multiple+Myeloma%22&lang=en+%7C+es+%7C+fr+%7C+de+%7C+ja+%7C+zh+%7C+ko+%7C+pt+%7C+ar+%7C+hi+%28default%3A+en%29&phase=phase2+%7C+phase3+%7C+both+%28default%3A+both%29&status=active+%7C+all+%28default%3A+active+%E2%80%94+recruiting+%2B+active+not+recruiting%29","name":"ClinicalIntelPulse","method":"GET","source":"bazaar:api.cdp.coinbase.com","fingerprint":"229e7db2c2f25479cdbb62ff2c6eabe68fe18b8a053a0e78ee7d763f55cf1402","advertisedPriceUsd":0.15},"source_id":1,"external_id":null}],"live_endpoint_metadata":{"x402_version":2,"resource_url":"https://clinicalintelpulse.theaslangroupllc.com/api/clinical/pipeline-scan","resource_description":"Clinical trial pipeline scan for any disease — all active Phase 2/3 trials with trial counts, sponsor landscape, geographic distribution, mechanism breakdown and pipeline density, across 400,000+ trials worldwide. For biotech-investing and pharma agents.","bazaar_extension":{"info":{"input":{"type":"http","method":"GET","queryParams":{"lang":"en | es | fr | de | ja | zh | ko | pt | ar | hi (default: en)","phase":"phase2 | phase3 | both (default: both)","status":"active | all (default: active — recruiting + active not recruiting)","condition":"Disease or condition — e.g. \"Non-Small Cell Lung Cancer\" | \"Alzheimer Disease\" | \"Type 2 Diabetes\" | \"Crohn Disease\" | \"Multiple Myeloma\""}},"output":{"type":"json","errors":{"400":{"example":{"error":"invalid request"},"description":"Invalid or missing parameter(s). Returned before the payment gate on paid requests, so a malformed call is never charged. JSON body: { error: <what is wrong and how to fix it> } plus usage hints."},"402":{"description":"Payment required — x402 v2 challenge; the accepts array lists scheme, network, and amount. Retry the same request with a PAYMENT-SIGNATURE (v2) or X-PAYMENT (v1) header. Verification is free."},"500":{"example":{"error":"upstream_failed"},"description":"Unexpected server error. If a payment settled without a usable result, contact info@theaslangroupllc.com with the settlement tx hash for a re-run or credit."}},"example":{"query_summary":{"condition":"Non-Small Cell Lung Cancer","status_filter":"RECRUITING,ACTIVE_NOT_RECRUITING","phases_searched":["PHASE2","PHASE3"]},"pipeline_totals":{"phase2_count":156,"phase3_count":89,"total_active":245},"phase3_highlights":[{"nctId":"NCT05116748","title":"Pembrolizumab + Carboplatin vs SOC in NSCLC","status":"RECRUITING","sponsor":"Merck","countries":["United States","Germany","Japan","South Korea"],"primaryCompletion":"2026-03"}],"sponsor_landscape":{"academic_sponsors":"ECOG-ACRIN, Alliance, NCI leading academic cooperative groups","emerging_biotechs":["Turning Point Therapeutics","Blueprint Medicines","Mirati Therapeutics"],"top_industry_sponsors":["Roche/Genentech (18 trials)","Bristol-Myers Squibb (14)","AstraZeneca (13)","Merck (12)","Pfizer (11)"]},"mechanism_breakdown":{"adc":18,"other":81,"bispecific":12,"targeted_therapy":41,"chemo_combinations":31,"io_checkpoint_inhibitors":62},"pipeline_assessment":"Extremely crowded pipeline — PD-1/L1 space saturated. ADCs and bispecifics represent highest differentiation potential. KRAS G12C targeted therapies emerging as new standard.","approved_drugs_context":"NSCLC has 30+ FDA-approved agents. Pipeline is additive rather than disruptive in most cases.","geographic_distribution":{"asia_pct":22,"other_pct":5,"europe_pct":28,"us_trials_pct":45,"most_active_countries":["United States","China","Germany","South Korea","Japan"]}}}},"schema":{"type":"object","$schema":"https://json-schema.org/draft/2020-12/schema","required":["input"],"properties":{"input":{"type":"object","required":["type","method"],"properties":{"type":{"type":"string","const":"http"},"method":{"enum":["GET","HEAD","DELETE"],"type":"string"},"queryParams":{"type":"object","properties":{"lang":{"type":"string"},"phase":{"type":"string"},"status":{"type":"string"},"condition":{"type":"string"}}}},"additionalProperties":false},"output":{"type":"object","required":["type"],"properties":{"type":{"type":"string"},"errors":{"type":"object","description":"Documented error responses, keyed by HTTP status code","additionalProperties":{"type":"object","required":["description"],"properties":{"example":{"type":"object"},"description":{"type":"string"}}}},"example":{"type":"object"}}}}}},"accepted_requirements":[{"raw":{"asset":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","extra":{"name":"USD Coin","version":"2"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"150000","scheme":"exact","network":"eip155:8453","maxTimeoutSeconds":300},"asset":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:8453","amountAtomic":"150000"},{"raw":{"asset":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","extra":{"name":"GatewayWalletBatched","version":"1","verifyingContract":"0x77777777dcc4d5a8b6e418fd04d8997ef11000ee"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"150000","scheme":"exact","network":"eip155:8453","maxTimeoutSeconds":604900},"asset":"0x833589fCD6eDb6E08f4c7C32D4f71b54bdA02913","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:8453","amountAtomic":"150000"},{"raw":{"asset":"EPjFWdd5AufqSSqeM2qN1xzybapC8G4wEGGkZwyTDt1v","extra":{"feePayer":"BFK9TLC3edb13K6v4YyH3DwPb5DSUpkWvb7XnqCL9b4F"},"payTo":"985iFjbnGQ3dJcwXnfRCMSrH4Jnc3kW1N6msR64B5KX1","amount":"150000","scheme":"exact","network":"solana:5eykt4UsFv8P8NJdTREpY1vzqKqZKvdp","maxTimeoutSeconds":300},"asset":"EPjFWdd5AufqSSqeM2qN1xzybapC8G4wEGGkZwyTDt1v","payTo":"985iFjbnGQ3dJcwXnfRCMSrH4Jnc3kW1N6msR64B5KX1","scheme":"exact","network":"solana:5eykt4UsFv8P8NJdTREpY1vzqKqZKvdp","amountAtomic":"150000"},{"raw":{"asset":"0x3c499c542cEF5E3811e1192ce70d8cC03d5c3359","extra":{"name":"USD Coin","version":"2"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"150000","scheme":"exact","network":"eip155:137","maxTimeoutSeconds":300},"asset":"0x3c499c542cEF5E3811e1192ce70d8cC03d5c3359","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:137","amountAtomic":"150000"},{"raw":{"asset":"0xaf88d065e77c8cC2239327C5EDb3A432268e5831","extra":{"name":"USD Coin","version":"2"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"150000","scheme":"exact","network":"eip155:42161","maxTimeoutSeconds":300},"asset":"0xaf88d065e77c8cC2239327C5EDb3A432268e5831","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:42161","amountAtomic":"150000"},{"raw":{"asset":"0x79A02482A880bCe3F13E09da970dC34dB4cD24D1","extra":{"name":"USDC","version":"2"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"150000","scheme":"exact","network":"eip155:480","maxTimeoutSeconds":300},"asset":"0x79A02482A880bCe3F13E09da970dC34dB4cD24D1","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:480","amountAtomic":"150000"},{"raw":{"asset":"0x754704Bc059F8C67012fEd69BC8A327a5aafb603","extra":{"name":"USDC","version":"2"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"150000","scheme":"exact","network":"eip155:143","maxTimeoutSeconds":300},"asset":"0x754704Bc059F8C67012fEd69BC8A327a5aafb603","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:143","amountAtomic":"150000"},{"raw":{"asset":"0x779ded0c9e1022225f8e0630b35a9b54be713736","extra":{"name":"USD₮0","version":"1"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"150000","scheme":"exact","network":"eip155:196","maxTimeoutSeconds":300},"asset":"0x779ded0c9e1022225f8e0630b35a9b54be713736","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:196","amountAtomic":"150000"},{"raw":{"asset":"0xb88339CB7199b77E23DB6E890353E22632Ba630f","extra":{"name":"USDC","version":"2"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"150000","scheme":"exact","network":"eip155:999","maxTimeoutSeconds":300},"asset":"0xb88339CB7199b77E23DB6E890353E22632Ba630f","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:999","amountAtomic":"150000"},{"raw":{"asset":"31566704","extra":{"feePayer":"ZMFK2OI7ZBD2U27ISERZC4S6LKM6WMFJPZQ4MYNJDZ2VNBNMBA67RA22AA"},"payTo":"62A253YPATFNJCPRKID3FKD77MYJFNTVRYRP4B4JWG36EGLPY7UXFWGI7I","amount":"150000","scheme":"exact","network":"algorand:wGHE2Pwdvd7S12BL5FaOP20EGYesN73k","maxTimeoutSeconds":300},"asset":"31566704","payTo":"62A253YPATFNJCPRKID3FKD77MYJFNTVRYRP4B4JWG36EGLPY7UXFWGI7I","scheme":"exact","network":"algorand:wGHE2Pwdvd7S12BL5FaOP20EGYesN73k","amountAtomic":"150000"},{"raw":{"asset":"XRP","extra":{"invoiceId":"0EF5EE18B3CF44559F1503F6E0BA510B","sourceTag":804681468},"payTo":"rMnHeutYALco8RYFVcmuU4BCgSzBpPEh32","amount":"150000","scheme":"exact","network":"xrpl:0","maxTimeoutSeconds":300},"asset":"XRP","payTo":"rMnHeutYALco8RYFVcmuU4BCgSzBpPEh32","scheme":"exact","network":"xrpl:0","amountAtomic":"150000"},{"raw":{"asset":"524C555344000000000000000000000000000000","extra":{"issuer":"rMxCKbEDwqr76QuheSUMdEGf4B9xJ8m5De","invoiceId":"B69C458AC46A4EFA88BB1A18A21C23C0","sourceTag":804681468},"payTo":"rMnHeutYALco8RYFVcmuU4BCgSzBpPEh32","amount":"0.15","scheme":"exact","network":"xrpl:0","maxTimeoutSeconds":300},"asset":"524C555344000000000000000000000000000000","payTo":"rMnHeutYALco8RYFVcmuU4BCgSzBpPEh32","scheme":"exact","network":"xrpl:0","amountAtomic":"0.15"},{"raw":{"asset":"0x8d0D000Ee44948FC98c9B98A4FA4921476f08B0d","extra":{"name":"World Liberty Financial USD","version":"1","signerAddress":"0x34F7a661160780Ce1346e6D7B96D2bE244590899","assetTransferMethod":"eip3009"},"payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","amount":"150000000000000000","scheme":"exact","network":"eip155:56","maxTimeoutSeconds":300},"asset":"0x8d0D000Ee44948FC98c9B98A4FA4921476f08B0d","payTo":"0x50ab2018c06c6E4eAA9BA52057Eb55eD284912fc","scheme":"exact","network":"eip155:56","amountAtomic":"150000000000000000"}],"bazaar_compatible":true,"bazaar_validated_at":"2026-09-14 16:30:14.384+00","bazaar_validation_error":null},"sonar_metrics":{"score":0.5403,"uptime":1,"paid_success_rate":0,"valid_result_rate":null,"latency_p50":578,"latency_p90":6702,"price_drift_pct":0},"cdp_indexed":false,"confidence":"medium"}